Isolation and identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and vaccinia virus antiviral activity

References

• Aoki C, Hartati S, Santi MR, Lydwina Firdaus R, Hanafi M, Kardono LBS, Yohko S, Pratiwi S, Hak H. 2014. Isolation and identification of substances with anti-hepatitis C cirus activities from Kalanchoe pinnata. Int J Pharm Pharm Sci. 6:211–215.
   Google Scholar
• Bray M, Wright ME. 2003. Progressive Vaccinia. Clin Infect Dis. 36:766–774.
   PubMed Web of Science ®Google Scholar
• Castelo-Soccio L, Bernardin R, Stern J, Goldstein SA, Kovarik C. 2010. Successful treatment of acyclovir-resistant Herpes simplex virus with intralesional cidofovir. Arch Dermatol. 146:124–126.
   PubMedGoogle Scholar
• Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2007. Draft guidance for industry on smallpox (Variola) infection: developing drugs for treatment or prevention; availability. Docket No. 2007D-0439.
   Google Scholar
• Coen DM, Schaffer PA. 1980. Two distinct loci confer resistance to acycloguanosine in Herpes simplex virus type 1. Proc Natl Acad Sci USA. 77:2265–2269.
   PubMed Web of Science ®Google Scholar
• Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, Rozenheim M, Baumelou A, Dohin E, Gentilini M, et al. 1989. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 9:316–321.
   PubMed Web of Science ®Google Scholar
• Earl PL, Americo JL, Moss B. 2003. Development and use of a Vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol. 77:10684–10688.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat. 5:88–114.
   PubMed Web of Science ®Google Scholar
• Greer MR, Cates RG, Johnson FB, Lamnaouer D, Ohai L. 2010. Activity of acetone and methanol extracts from thirty-one medicinal plant species against Herpes simplex virus types 1 and 2. Pharm Biol. 48:1031–1037.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Committee on the Assessment of Future Scientific Needs for Live Variola Virus. 1999. Assessment of future scientific needs for live variola virus. Washington DC: National Academies Press.
   Google Scholar
• Izzedine H, Launay-Vacher V, Deray G. 2005. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 45:804–817.
   PubMed Web of Science ®Google Scholar
• James W, Berger T, Elston D. 2006. Andrews' diseases of the skin: clinical dermatology. London, UK: Saunders Elsevier.
   Google Scholar
• Johnson MC, Damon IK, Karem KL. 2008. A rapid, high-throughput Vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein. J Virol Methods. 150:14–20.
   PubMed Web of Science ®Google Scholar
• Lane JM, Ruben FL, Neff JM, Millar JD. 1969. Complications of smallpox vaccination, 1968. N Engl J Med. 281:1201–1208.
   PubMed Web of Science ®Google Scholar
• LeDuc JW, Damon I, Relman DA, Huggins J, Jahrling PB. 2002. Smallpox research activities: US interagency collaboration, 2001. Emerg Infect Dis. 8:743–745.
   PubMed Web of Science ®Google Scholar
• Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, Newman LM. 2015a. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One. 10:e0140765.
   PubMed Web of Science ®Google Scholar
• Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. 2015b. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. PLoS One. 10:e114989.
   PubMed Web of Science ®Google Scholar
• Luker G, Chow C, Richards DF, Johnson FB. 1991. Suitability of infection of cells in suspension for detection of herpes simplex virus. J Clin Microbiol. 29:1554–1557.
   PubMed Web of Science ®Google Scholar
• Moss B. 2013. Poxviridae. In: Knipe DM, Howley PM, editor. Fields virology. Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; p. 2130.
   Google Scholar
• Mucker EM, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM, Holman RC, Carroll D, Gallardo N, Olson VA, et al. 2013. Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother. 57:6246–6253.
   PubMed Web of Science ®Google Scholar
• Oberg B. 1989. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 40:213–285.
   PubMed Web of Science ®Google Scholar
• Pottage JC, Jr., Kessler HA. 1995. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis. 4:115–124.
   PubMedGoogle Scholar
• Reed LJ, Muencha H. 1938. Simple method of estimating fifty per cent endpoints. Am J Epidemiol. 27:493–497.
   Google Scholar
• Stránská R, Schuurman R, Nienhuis E, Goedegebuure IW, Polman M, Weel JF, Wertheim-Van Dillen PM, Berkhout RJ, van Loon AM. 2005. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: Prevalence and characterization. J Clin Virol. 32:7–18.
   PubMed Web of Science ®Google Scholar
• Stránská R, van Loon AM, Polman M, Beersma MF, Bredius RG, Lankester AC, Meijer E, Schuurman R. 2004. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. Antivir Ther (Lond.). 9:565–575.
   PubMed Web of Science ®Google Scholar
• Supratman U, Fujita T, Akiyama K, Hayashi H, Murakami A, Sakai H, Koshimizu K, Ohigashi H. 2001. Anti-tumor promoting activity of bufadienolides from Kalanchoe pinnata and K. daigremontiana x tubiflora. Biosci Biotechnol Biochem. 65:947–949.
   PubMed Web of Science ®Google Scholar